Study of Blood Samples From Patients With Osteosarcoma
Study Details
Study Description
Brief Summary
This research trial studies blood samples from patients with osteosarcoma. Studying the genes found in samples of blood from patients with osteosarcoma may help doctors identify biomarkers related to the disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
PRIMARY OBJECTIVE:
- Conduct a large-scale candidate gene association study in osteosarcoma (OS) using cases from the national Children's Oncology Group (COG) OS biology study (P9851 and successor study AOST06B1).
SECONDARY OBJECTIVES:
-
Conduct a genome-wide association study (GWAS) of OS. II. Fine-map genomic regions associated with OS to identify putative functional loci.
-
Conduct whole-exome sequencing of germline OS deoxyribonucleic acid (DNA) samples.
-
Investigate the functional implications of promising genetic variants associated with OS.
OUTLINE:
Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Ancillary-correlative (osteosarcoma genetic risk) Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure. |
Other: laboratory biomarker analysis
Correlative studies
|
Outcome Measures
Primary Outcome Measures
- Hardy-Weinberg equilibrium on all SNPs [Baseline]
Determined on all SNPs by chi-square tests.
- SNPs associated with OS [Baseline]
Logistic regression will be used to estimate odds ratios and 95% confidence intervals for the association between each SNP and OS under co-dominant, dominant and recessive genetic models. Stratified analyses will be conducted to examine sex, tumor subtype and outcome differences.
- Gene-gene interactions [Baseline]
Assessed using a multiplicative model. Haplotypes will be constructed using both Bayesian and expectation-maximization algorithms. Differences between cases and controls will be evaluated with HaploStats which uses haplotype posterior probabilities as weights to update the regression coefficients in an iterative manner.
- Survival outcomes [Baseline]
Kaplan-Meier survival curves will be used to determine outcome relative to genotype.
- Whole-exome variant loci [Baseline]
Annotation and filtering of each whole-exome variant locus will be performed using a custom software pipeline. Variants in >= 2 OS cases will be validated, and then subsequently replicated in additional OS cases (samples previously received for the GWAS from international collaborators). Variants will also be evaluated for presence in known biologically plausible pathways and genes.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Blood samples collected from clinical trials COG-P9851 and COG-AOST06B1
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Children's Oncology Group | Arcadia | California | United States | 91006-3776 |
Sponsors and Collaborators
- Children's Oncology Group
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Sharon Savage, MD, Children's Oncology Group
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AOST08B1
- NCI-2011-02192
- COG-AOST08B1
- AOST08B1
- AOST08B1
- U10CA098543